Immunological and Autoimmune Disorders

Zymeworks Daiichi I-O deal could potentially be worth USD 485 million Zymeworks and Daiichi Sankyo teamed up in 2016 on bispecific antibodies at that time the financial details were kept under the curtains. The pair is now entering into a new license agreement with a potential deal worth of around USD 484.7 million. The new agreement will grant the Japanese pharma two more licenses for an upfront technology access fee of USD 18 million as per the reports. Celsius grabs USD 65 million funding to develop precision drugs for cancer, autoimmune disease Celsius Therapeutics is all set to develop single-cell genomic sequencing based therapeutics. After bagging USD 65 million...